Press Releases

 

General

  Date Title and Summary View
Jun 14, 2017
LAWRENCEVILLE, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2017 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550...
Jun 5, 2017
100% disease control rate and 86% objective response rate reported All patients at the highest dose demonstrated an objective response rate - partial (80%) or complete (20%) response rate At the highest dose, 100% of patients achieved a R0, margin-negative, resection LAWRENCEVILLE, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporati...
May 26, 2017
LAWRENCEVILLE, N.J., May 26, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced today that it is effecting a 1 for 14 reverse stock split of its common stock which will be effective for trading purposes as of the commencement of trading on Tuesday, May 30, 2017.  As of that date, each fourt...
May 12, 2017
LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2017 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-...
May 5, 2017
LAWRENCEVILLE, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
May 4, 2017
LAWRENCEVILLE, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced updated additional clinical and translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of ne...
Apr 20, 2017
LAWRENCEVILLE, N.J., April 20, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients wi...
Apr 13, 2017
Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved with ThermoDox® Combined with Mild Local Hyperthermia Compared to Free Doxorubicin Alone The Study Reinforces ThermoDox's Unique, Proprietary Mechanism of Action LAWRENCEVILLE, N.J., April 13, 2017 (GLOBE NEWSWIRE) -- Celsion Corpo...
Mar 16, 2017
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GE...
Mar 9, 2017
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
Share This